Randomized Trialhigh evidence

Myocardial Responses to Eplontersen in Transthyretin Amyloid Cardiomyopathy: The CARDIO-TTRansform CMR study.

Circulation·November 9, 2026·PMID 43002382

Why it matters

Transthyretin-lowering therapies are known to improve clinical outcomes in ATTR-CM, but their direct myocardial effects have been unclear. This randomized CMR evidence shows that eplontersen reduces amyloid burden and improves cardiac structure and function, providing mechanistic insight and supporting serial CMR as a tool for monitoring treatment response.

Infographic summary of Myocardial Responses to Eplontersen in Transthyretin Amyloid Cardiomyopathy: The CARDIO-TTRansform CMR study.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled